Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial.

Saltarella I, Morabito F, Giuliani N, Terragna C, Omedè P, Palumbo A, Bringhen S, De Paoli L, Martino E, Larocca A, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Dammacco F, Boccadoro M, Vacca A, Ria R.

J Hematol Oncol. 2019 Jan 9;12(1):4. doi: 10.1186/s13045-018-0691-4.

2.

Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.

Ferrero S, Ladetto M, Drandi D, Cavallo F, Genuardi E, Urbano M, Caltagirone S, Grasso M, Rossini F, Guglielmelli T, Cangialosi C, Liberati AM, Callea V, Carovita T, Crippa C, De Rosa L, Pisani F, Falcone AP, Pregno P, Oliva S, Terragna C, Musto P, Passera R, Boccadoro M, Palumbo A.

Leukemia. 2015 Mar;29(3):689-95. doi: 10.1038/leu.2014.219. Epub 2014 Jul 16.

PMID:
25027515
3.

Circulating miRNA markers show promise as new prognosticators for multiple myeloma.

Rocci A, Hofmeister CC, Geyer S, Stiff A, Gambella M, Cascione L, Guan J, Benson DM, Efebera YA, Talabere T, Dirisala V, Smith EM, Omedè P, Isaia G, De Luca L, Rossi D, Gentili S, Uccello G, Consiglio J, Ria R, Benevolo G, Bringhen S, Callea V, Weiss B, Ferro A, Magarotto V, Alder H, Byrd JC, Boccadoro M, Marcucci G, Palumbo A, Pichiorri F.

Leukemia. 2014 Sep;28(9):1922-6. doi: 10.1038/leu.2014.155. Epub 2014 May 12. No abstract available.

4.

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

Foà R, Del Giudice I, Cuneo A, Del Poeta G, Ciolli S, Di Raimondo F, Lauria F, Cencini E, Rigolin GM, Cortelezzi A, Nobile F, Callea V, Brugiatelli M, Massaia M, Molica S, Trentin L, Rizzi R, Specchia G, Di Serio F, Orsucci L, Ambrosetti A, Montillo M, Zinzani PL, Ferrara F, Morabito F, Mura MA, Soriani S, Peragine N, Tavolaro S, Bonina S, Marinelli M, De Propris MS, Starza ID, Piciocchi A, Alietti A, Runggaldier EJ, Gamba E, Mauro FR, Chiaretti S, Guarini A.

Am J Hematol. 2014 May;89(5):480-6. doi: 10.1002/ajh.23668. Epub 2014 Feb 18.

5.

Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials.

Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, Rossi D, Cavalli M, Wijermans P, Ria R, Offidani M, Lahuerta JJ, Liberati AM, Mina R, Callea V, Schaafsma M, Cerrato C, Marasca R, Franceschini L, Evangelista A, Teruel AI, van der Holt B, Montefusco V, Ciccone G, Boccadoro M, San Miguel J, Sonneveld P, Palumbo A.

Haematologica. 2013 Jun;98(6):980-7. doi: 10.3324/haematol.2012.075051. Epub 2013 Feb 26.

6.

B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia.

Maura F, Visco C, Falisi E, Reda G, Fabris S, Agnelli L, Tuana G, Lionetti M, Guercini N, Novella E, Nichele I, Montaldi A, Autore F, Gregorini A, Barcellini W, Callea V, Mauro FR, Laurenti L, Foà R, Neri A, Rodeghiero F, Cortelezzi A.

Am J Hematol. 2013 Jan;88(1):32-6. doi: 10.1002/ajh.23342. Epub 2012 Oct 31.

7.

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma.

Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D, Crippa C, Boccadoro M, Perrone G, Falcone A, Nozzoli C, Zambello R, Masini L, Furlan A, Brioli A, Derudas D, Ballanti S, Dessanti ML, De Stefano V, Carella AM, Marcatti M, Nozza A, Ferrara F, Callea V, Califano C, Pezzi A, Baraldi A, Grasso M, Musto P, Palumbo A; GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network.

Blood. 2012 Jul 5;120(1):9-19. doi: 10.1182/blood-2012-02-408898. Epub 2012 Apr 12.

8.

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients.

Cortelezzi A, Gritti G, Laurenti L, Cuneo A, Ciolli S, Di Renzo N, Musto P, Mauro FR, Cascavilla N, Falchi L, Zallio F, Callea V, Maura F, Martinelli S, Piciocchi A, Reda G, Foà R; GIMEMA Chronic Lymphoproliferative Disorders Working Party.

Br J Haematol. 2012 Feb;156(4):481-9. doi: 10.1111/j.1365-2141.2011.08965.x. Epub 2011 Dec 9.

9.

The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience.

Laurenti L, Tarnani M, Nichele I, Ciolli S, Cortelezzi A, Forconi F, Rossi D, Mauro FR, D'Arena G, Del Poeta G, Montanaro M, Morabito F, Musolino C, Callea V, Falchi L, Tedeschi A, Ambrosetti A, Gaidano G, Leone G, Foà R.

Am J Hematol. 2011 Dec;86(12):1007-12. doi: 10.1002/ajh.22171. Epub 2011 Sep 22.

10.

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M.

J Clin Oncol. 2011 Mar 10;29(8):986-93. doi: 10.1200/JCO.2010.31.6844. Epub 2011 Jan 31.

PMID:
21282540
11.

Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion.

Mosca L, Fabris S, Lionetti M, Todoerti K, Agnelli L, Morabito F, Cutrona G, Andronache A, Matis S, Ferrari F, Gentile M, Spriano M, Callea V, Festini G, Molica S, Deliliers GL, Bicciato S, Ferrarini M, Neri A.

Clin Cancer Res. 2010 Dec 1;16(23):5641-53. doi: 10.1158/1078-0432.CCR-10-0151. Epub 2010 Oct 14.

12.

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, Benevolo G, Callea V, Baldini L, Morabito F, Grasso M, Leonardi G, Rizzo M, Falcone AP, Gottardi D, Montefusco V, Musto P, Petrucci MT, Ciccone G, Boccadoro M.

J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.

PMID:
20940200
13.

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A.

Blood. 2010 Dec 2;116(23):4745-53. doi: 10.1182/blood-2010-07-294983. Epub 2010 Aug 31. Erratum in: Blood. 2012 Dec 20;120(26):5250.

14.

More on the determination of Ki-67 as a novel potential prognostic marker in B-cell chronic lymphocytic leukemia.

Morabito F, Cutrona G, Gentile M, Loiacono F, Matis S, Recchia AG, Gigliotti V, Callea V, Zupo S, Ferrarini M.

Leuk Res. 2010 Dec;34(12):e326-8. doi: 10.1016/j.leukres.2010.07.036. Epub 2010 Aug 17. No abstract available.

PMID:
20723976
15.

Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.

Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L, Crippa C, De Rosa L, Pregno P, Grasso M, Liberati AM, Caravita T, Pisani F, Guglielmelli T, Callea V, Musto P, Cangialosi C, Passera R, Boccadoro M, Palumbo A.

J Clin Oncol. 2010 Apr 20;28(12):2077-84. doi: 10.1200/JCO.2009.23.7172. Epub 2010 Mar 22.

PMID:
20308672
16.

Prognostic relevance of in vitro response to cell stimulation via surface IgD in binet stage a CLL.

Morabito F, Cutrona G, Gentile M, Fabbi M, Matis S, Colombo M, Reverberi D, Megna M, Spriano M, Callea V, Vigna E, Rossi E, Lucia E, Festini G, Zupo S, Molica S, Neri A, Ferrarini M.

Br J Haematol. 2010 Apr;149(1):160-3. doi: 10.1111/j.1365-2141.2009.08032.x. Epub 2009 Dec 8. No abstract available.

PMID:
19995391
17.

Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study.

Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M, Ria R, Pisani F, Cangialosi C, Caravita T, Levi A, Meloni G, Nozza A, Pregno P, Gabbas A, Callea V, Rizzo M, Annino L, De Stefano V, Musto P, Baldi I, Cavallo F, Petrucci MT, Massaia M, Boccadoro M.

Blood. 2010 Mar 11;115(10):1873-9. doi: 10.1182/blood-2009-09-241737. Epub 2009 Dec 1. Erratum in: Blood. 2010 Sep 23;116(12):2195.

18.

Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.

Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M.

Eur J Haematol. 2010 Mar;84(3):223-8. doi: 10.1111/j.1600-0609.2009.01385.x. Epub 2009 Nov 23.

PMID:
19930441
19.

The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience.

Molica S, Mauro FR, Callea V, Giannarelli D, Lauria F, Rotoli B, Cortelezzi A, Liso V, Foà R.

Haematologica. 2010 Mar;95(3):464-9. doi: 10.3324/haematol.2009.011767. Epub 2009 Nov 10.

20.

Proposal and validation of prognostic scoring systems for IgG and IgA monoclonal gammopathies of undetermined significance.

Rossi F, Petrucci MT, Guffanti A, Marcheselli L, Rossi D, Callea V, Vincenzo F, De Muro M, Baraldi A, Villani O, Musto P, Bacigalupo A, Gaidano G, Avvisati G, Goldaniga M, Depaoli L, Baldini L.

Clin Cancer Res. 2009 Jul 1;15(13):4439-45. doi: 10.1158/1078-0432.CCR-08-3150. Epub 2009 Jun 9.

21.

Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia.

Morabito F, Cutrona G, Gentile M, Matis S, Todoerti K, Colombo M, Sonaglio C, Fabris S, Reverberi D, Megna M, Spriano M, Lucia E, Rossi E, Callea V, Mazzone C, Festini G, Zupo S, Molica S, Neri A, Ferrarini M.

Br J Haematol. 2009 Jun;146(1):44-53. doi: 10.1111/j.1365-2141.2009.07703.x. Epub 2009 May 6.

PMID:
19438486
22.

Response-guided ABVD chemotherapy plus involved-field radiation therapy for intermediate-stage Hodgkin lymphoma in the pre-positron emission tomography era: a Gruppo Italiano Studio Linfomi (GISL) prospective trial.

Iannitto E, Minardi V, Gobbi PG, Calvaruso G, Tripodo C, Marcheselli L, Luminari S, Merli F, Baldini L, Stelitano C, Callea V, Petrini M, Angrilli F, Quarta G, Vallisa D, Molica S, Liardo E, Polimeno G, Brugiatelli M, Federico M.

Clin Lymphoma Myeloma. 2009 Apr;9(2):138-44. doi: 10.3816/CLM.2009.n.034.

PMID:
19406724
23.

Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia.

Fabris S, Mosca L, Todoerti K, Cutrona G, Lionetti M, Intini D, Matis S, Colombo M, Agnelli L, Gentile M, Spriano M, Callea V, Festini G, Molica S, Lambertenghi Deliliers G, Morabito F, Ferrarini M, Neri A.

Genes Chromosomes Cancer. 2008 Sep;47(9):781-93. doi: 10.1002/gcc.20579.

PMID:
18521849
24.

Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial.

Palumbo A, Bringhen S, Liberati AM, Caravita T, Falcone A, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, Derudas D, Dore F, Cavallo F, Gay F, Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M.

Blood. 2008 Oct 15;112(8):3107-14. doi: 10.1182/blood-2008-04-149427. Epub 2008 May 27.

25.

Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma.

Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, Caravita T, Morabito F, Magarotto V, Ruggeri M, Avonto I, Musto P, Cascavilla N, Bruno B, Boccadoro M.

Ann Oncol. 2008 Jun;19(6):1160-5. doi: 10.1093/annonc/mdn018. Epub 2008 Mar 6.

PMID:
18326520
26.

Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells.

Cutrona G, Colombo M, Matis S, Fabbi M, Spriano M, Callea V, Vigna E, Gentile M, Zupo S, Chiorazzi N, Morabito F, Ferrarini M.

Haematologica. 2008 Mar;93(3):413-22. doi: 10.3324/haematol.11646. Epub 2008 Feb 20.

27.

Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage.

Ladetto M, De Marco F, Benedetti F, Vitolo U, Patti C, Rambaldi A, Pulsoni A, Musso M, Liberati AM, Olivieri A, Gallamini A, Pogliani E, Rota Scalabrini D, Callea V, Di Raimondo F, Pavone V, Tucci A, Cortelazzo S, Levis A, Boccadoro M, Majolino I, Pileri A, Gianni AM, Passera R, Corradini P, Tarella C; Gruppo Italiano Trapianto di Midollo Osseo (GITMO); Intergruppo Italiano Linfomi (IIL).

Blood. 2008 Apr 15;111(8):4004-13. doi: 10.1182/blood-2007-10-116749. Epub 2008 Jan 31.

28.

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.

Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, Cangialosi C, Caravita T, Morabito F, Musto P, Bringhen S, Falco P, Avonto I, Cavallo F, Boccadoro M; Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto.

Blood. 2007 Apr 1;109(7):2767-72.

29.

Incidence of second neoplasia in patients with B-cell chronic lymphocytic leukemia treated with chlorambucil maintenance chemotherapy.

Callea V, Brugiatelli M, Stelitano C, Gentile M, Nobile F, Morabito F.

Leuk Lymphoma. 2006 Nov;47(11):2314-20.

PMID:
17107903
30.

Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients.

Martino M, Console G, Callea V, Stelitano C, Massara E, Irrera G, Messina G, Morabito F, Iacopino P.

Eur J Haematol. 2007 Jan;78(1):35-40. Epub 2006 Oct 17.

PMID:
17042773
31.

Prolonged survival and low incidence of late toxic sequelae in advanced follicular lymphoma treated with a TBI-free autografting program: updated results of the multicenter consecutive GITMO trial.

Ladetto M, Vallet S, Benedetti F, Vitolo U, Martelli M, Callea V, Patti C, Coser P, Perrotti A, Sorio M, Boccomini C, Pulsoni A, Stelitano C, Scimè R, Boccadoro M, Rosato R, De Marco F, Zanni M, Corradini P, Tarella C.

Leukemia. 2006 Oct;20(10):1840-7. Epub 2006 Aug 24.

PMID:
16932351
32.

B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens.

Sabattini E, Orduz R, Campidelli C, Zinzani PL, Callea V, Zupo S, Cutrona G, Morabito F, Ferrarini M, Pileri S.

J Clin Pathol. 2007 Jun;60(6):627-32. Epub 2006 Aug 17.

33.

High-dose therapy and autologous peripheral blood stem cells transplantation followed by a very low reduced intensity regimen with fludarabine + cyclophosphamide and allograft improve complete remission rate in de novo multiple myeloma patients.

Martino M, Console G, Irrera G, Praticò G, Stelitano C, Callea V, Morabito F, Quartarone E, Musolino C, Piro E, Brugiatelli M, Iacopino P.

Am J Hematol. 2006 Dec;81(12):973-8.

34.

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.

Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, Cangialosi C, Grasso M, Rossini F, Galli M, Catalano L, Zamagni E, Petrucci MT, De Stefano V, Ceccarelli M, Ambrosini MT, Avonto I, Falco P, Ciccone G, Liberati AM, Musto P, Boccadoro M; Italian Multiple Myeloma Network, GIMEMA.

Lancet. 2006 Mar 11;367(9513):825-31.

PMID:
16530576
35.

IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia.

Bagnara D, Callea V, Stelitano C, Morabito F, Fabris S, Neri A, Zanardi S, Ghiotto F, Ciccone E, Grossi CE, Fais F.

Br J Haematol. 2006 Apr;133(1):50-8.

PMID:
16512828
36.

Splenic marginal zone lymphoma: a prognostic model for clinical use.

Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, Morra E, Gambacorta M, Cortelazzo S, Tucci A, Ungari M, Ambrosetti A, Menestrina F, Orsucci L, Novero D, Pulsoni A, Frezzato M, Gaidano G, Vallisa D, Minardi V, Tripodo C, Callea V, Baldini L, Merli F, Federico M, Franco V, Iannitto E; Integruppo Italiano Linfomi.

Blood. 2006 Jun 15;107(12):4643-9. Epub 2006 Feb 21.

37.

Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma.

Iannitto E, Minardi V, Callea V, Stelitano C, Calvaruso G, Tripodo C, Quintini G, De Cantis S, Ambrosetti A, Pizzolo G, Franco V, Florena AM, Abbadessa V.

Eur J Haematol. 2006 Feb;76(2):134-40.

PMID:
16405434
38.

The role of high-dose therapy and autologous stem cell transplantation in patients with primary refractory Hodgkin's lymphoma: a report from the Gruppo Italiano per lo Studio dei Linfomi (GISL).

Morabito F, Stelitano C, Luminari S, Mammi C, Marcheselli L, Callea V, Gentile M, Polimeno G, Merli F, Molica S, Gobbi P, Angrilli F, Brugiatelli M, Federico M.

Bone Marrow Transplant. 2006 Feb;37(3):283-8.

PMID:
16327815
39.

Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L, Neri A.

J Clin Oncol. 2005 Oct 10;23(29):7296-306. Epub 2005 Aug 29.

PMID:
16129847
40.

Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.

Palumbo A, Bertola A, Musto P, Caravita T, Callea V, Nunzi M, Grasso M, Falco P, Cangialosi C, Boccadoro M.

Cancer. 2005 Oct 1;104(7):1428-33.

41.

A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci.

Sellick GS, Webb EL, Allinson R, Matutes E, Dyer MJ, Jonsson V, Langerak AW, Mauro FR, Fuller S, Wiley J, Lyttelton M, Callea V, Yuille M, Catovsky D, Houlston RS.

Am J Hum Genet. 2005 Sep;77(3):420-9. Epub 2005 Aug 2.

42.

Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenstrom's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: proposal for a common prognostic scoring system.

Baldini L, Goldaniga M, Guffanti A, Broglia C, Cortelazzo S, Rossi A, Morra E, Colombi M, Callea V, Pogliani E, Ilariucci F, Luminari S, Morel P, Merlini G, Gobbi P.

J Clin Oncol. 2005 Jul 20;23(21):4662-8.

PMID:
16034042
43.

A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia.

Molica S, Mauro FR, Callea V, Gentile M, Giannarelli D, Lopez M, Lauria F, Rotoli B, Montanaro M, Cortelezzi A, Liso V, Mandelli F, Foa R; GIMEMA CLL Study Group.

Leuk Lymphoma. 2005 Apr;46(4):553-60.

PMID:
16032778
44.

Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation.

Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R, Stelitano C, Andreazzoli F, Guerrini F, Ciabatti E, Martino M, Nobile F, Iacopino P, Petrini M.

Leuk Res. 2005 Aug;29(8):961-6.

PMID:
15978948
45.

The CX3C chemokine fractalkine (CX3CL1) is detectable in serum of B cell chronic lymphocytic leukemia patients with lymph node involvement.

Morabito F, Merendino RA, Penna G, Cuzzola M, Stelitano C, Callea V, Di Pasquale G, Minciullo PL, Gangemi S.

Acta Haematol. 2005;113(2):152-4. No abstract available.

PMID:
15802897
46.

Lipid peroxidation and protein oxidation in patients affected by Hodgkin's lymphoma.

Morabito F, Cristani M, Saija A, Stelitano C, Callea V, Tomaino A, Minciullo PL, Gangemi S.

Mediators Inflamm. 2004 Dec;13(5-6):381-3.

47.

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.

Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A.

Oncogene. 2005 Apr 7;24(15):2461-73.

PMID:
15735737
48.

Role of anti-hepatitis C virus (HCV) treatment in HCV-related, low-grade, B-cell, non-Hodgkin's lymphoma: a multicenter Italian experience.

Vallisa D, Bernuzzi P, Arcaini L, Sacchi S, Callea V, Marasca R, Lazzaro A, Trabacchi E, Anselmi E, Arcari AL, Moroni C, Bertè R, Lazzarino M, Cavanna L.

J Clin Oncol. 2005 Jan 20;23(3):468-73.

PMID:
15659492
49.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
50.

Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients.

Martino M, Oliva E, Console G, Stelitano C, Fujo M, Messina G, Irrera G, Pucci G, Mandaglio R, Callea V, Nobile F, Iacopino P, Morabito F.

Support Care Cancer. 2005 Mar;13(3):182-7. Epub 2004 Oct 6.

PMID:
15480819

Supplemental Content

Loading ...
Support Center